Zacks Equity Research

About the Author Zacks Equity Research brings the decades of study and stock picking expertise of Zacks Investment Research to individual investors. Now, you don't need to be an investment bank or brokerage firm to get the professional power of Zacks' research. It's all available on Learn more about Zacks' history and company on our website.

Zack’s Bull of the Day: Rite Aid

Estimates have risen sharply for Rite Aid Corporation (NYSE:RAD) following the company’s better-than-expected fiscal 2015 third quarter results. Not only did Rite Aid crush earnings expectations, it beat revenue expectations thanks to a solid 5.4% jump in same-store sales. And management increased its full year sales and EPS guidance too.

Rite Aid is a Zacks Rank #1 (Strong Buy) stock.

Rite Aid Corporation is a drugstore chain with 4,570 stores. Approximately 70% of its total revenues comes from pharmacy sales. It is headquartered in Camp Hill, Pennsylvania and has a market cap of $7.2 billion.

Third Quarter Results

Rite Aid reported its fiscal 2015 third quarter results on December 18. Results came in well above expectations.

Earnings per share for Q3 was $0.10, doubling the Zacks Consensus Estimate of $0.05. It was also 150% increase from the same quarter last year. Revenues rose 5% to $6.692 billion, ahead of the consensus of $6.643 billion. Same-store sales increased a solid 5.4% year-over-year, driven by a 7.2% increase in pharmacy sales.

The gross profit margin expanded 42 basis points to 28.74% of revenues. Meanwhile, selling, general and administrative expenses declined 38 basis points to 25.29% of revenues. And total interest expense decreased more than 5% year-over-year. These factors helped drive a 44 basis point improvement in the net profit margin to 1.57% of revenues.

Estimates Rising

Following strong Q3 results, management raised its full year guidance for both same-store sales and EPS. The company now expects fiscal 2015 same-store sales within a range of 3.75-4.25%, up from prior guidance of 3.00-4.00%, and EPS of $0.31-$0.37, up from $0.22-$0.33.

This was also well above consensus at the time and prompted analysts to unanimously revise their estimates higher too, sending the stock to a Zacks Rank of 1 (Strong Buy).

The 2015 Zacks Consensus Estimate is now $0.34, within guidance, and up from $0.28 before the report. The 2016 consensus increased from $0.37 to $0.43 over the same period.

Rite Aid also reported solid top-line results for December on January 2. Same-store sales increased 5.3% year-over-year, driven once again by strong growth in pharmacy sales, which rose 7.3%.


Shares of Rite Aid have soared since the better-than-expected Q3 report. But valuation still looks reasonable with shares trading at 18x forward 12-month EPS, which is a slight discount to the industry median. Its enterprise value to cash flow ratio of 17x is also a slight discount to its peers.

The Bottom Line

With strong earnings momentum driven by solid top-line growth and expanding profit margins, along with reasonable valuation, shares of Rite Aid could very well continue to climb over the next several weeks.

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, blogger Zacks Investment Research has a total average return of+0.1% and a 47% success rate. Zacks Investment Research is Ranked #2237 out of 4128 Bloggers

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts